[Form 4] Gilead Sciences Inc Insider Trading Activity
Deborah H. Telman, Executive Vice President, Corporate Affairs & General Counsel of Gilead Sciences (GILD), reported two transactions on 09/10/2025. She was granted 1,315 restricted stock units (RSUs), each converting to one share, which vest over four years (25% at year one, then 6.25% quarterly). The RSU grant increased contingent ownership by 1,315 shares. On the same date she disposed of 634 shares in a sale at $115.25 per share. After these transactions she beneficially owned 43,402 shares (44,036 including the unvested RSUs). The Form 4 was signed by power of attorney on her behalf.
Deborah H. Telman, Vicepresidente Esecutivo per gli Affari Aziendali Corporate e Consigliere Generale di Gilead Sciences (GILD), ha riportato due transazioni il 09/10/2025. Le sono state attribuite 1.315 unità di azioni restritte (RSU), ciascuna delle quali si convertì in una azione, che maturano in quattro anni (il 25% al primo anno, poi il 6,25% trimestralmente). Il grant RSU ha aumentato la proprietà contingente di 1.315 azioni. Nella stessa data ha ceduto 634 azioni in una vendita al prezzo di $115,25 per azione. Dopo queste transazioni deteneva beneficialmente 43.402 azioni (44.036 inclusi gli RSU non maturi). Il Form 4 è stato firmato per procura per suo conto.
Deborah H. Telman, Vicepresidenta Ejecutiva de Asuntos Corporativos y Consejera General de Gilead Sciences (GILD), informó de dos transacciones el 09/10/2025. Se le otorgaron 1.315 unidades de acciones restringidas (RSU), cada una de las cuales se convierte en una acción, que vence en cuatro años (75% al año uno, luego 6.25% trimestralmente). La concesión de RSU aumentó la propiedad contingente en 1.315 acciones. En la misma fecha dispuso de 634 acciones en una venta a $115.25 por acción. Después de estas operaciones poseía de forma beneficiosa 43.402 acciones (44.036 incluyendo las RSU no vestidas). El Formulario 4 fue firmado por poder de representación en su nombre.
Deborah H. Telman, Gilead Sciences(GILD) 의 부사장 겸 기업 커뮤니케이션(또는 기업 관계) 및 일반 counsel,는 2025년 9월 10일에 두 건의 거래를 보고했다. 그녀는 1,315개의 제한 주식 단위(RSU)를 부여받았으며, 각 단위는 한 주식으로 전환되며 4년 동안 vesting된다(1년 차에 25%, 그 다음 매 분기 6.25%). RSU 부여는 거주 지분을 1,315주 증가시켰다. 같은 날 그녀는 634주를 처분했고 주당 가격은 $115.25였다. 이 거래 후 그녀의 실제 보유 주식은 43,402주였으며, 미 vest RSU를 포함하면 44,036주이다. Form 4는 그녀를 대신해 위임장으로 서명되었다.
Deborah H. Telman, Vice‑Présidente Exécutive des Affaires Corporatives et Conseillère Juridique Générale de Gilead Sciences (GILD), a déclaré deux transactions le 09/10/2025. Elle a reçu 1 315 unités d’actions restreintes (RSU), chacune se convertissant en une action, qui vestent sur quatre ans (25 % la première année, puis 6,25 % trimestriellement). L’octroi de RSU a augmenté la propriété éventuelle de 1 315 actions. À la même date, elle a cédé 634 actions lors d’une vente à $115,25 par action. Après ces transactions, elle détenait de manière bénéficiaire 43 402 actions (44 036 actions en incluant les RSU non vestées). Le Form 4 a été signé par procuration en son nom.
Deborah H. Telman, Executive Vice President, Corporate Affairs & General Counsel von Gilead Sciences (GILD), meldete zwei Transaktionen am 09/10/2025. Ihr wurden 1.315 Restricted Stock Units (RSUs) gewährt, von denen jede in eine Aktie umgewandelt wird und über vier Jahre vestet (25 % im ersten Jahr, dann vierteljährlich 6,25 %). Die RSU-Zuteilung erhöhte das contingent ownership um 1.315 Aktien. Am gleichen Datum veräußerte sie 634 Aktien zu einem Preis von $115,25 je Aktie. Nach diesen Transaktionen hielt sie vorteilhafterweise 43.402 Aktien (44.036 einschließlich der noch nicht vesteten RSUs). Das Form 4 wurde in Vollmacht zu ihren Gunsten unterzeichnet.
دِبورا إتش. تيلمان، نائبة الرئيس التنفيذية للشؤون المؤسسية والمستشارة العامة لشركة جيليد ساينسز (GILD)، ذكرت انقلابين ماليين في 09/10/2025. تم منحها 1,315 وحدة أسهم مقيدة (RSUs)، كلٌّ منها يتحول إلى سهم واحد، وتخضع للاستحقاق على مدى أربع سنوات (25% في السنة الأولى، ثم 6.25% ربع سنويًا). منح RSU زاد الملكية غير المؤكدة بمقدار 1,315 سهمًا. في نفس التاريخ قامت ببيع 634 سهمًا بسعر $115.25 للسهم. بعد هذه المعاملات كانت تملك بشكل منتفع 43,402 سهمًا (44,036 بما فيها RSUs غير المستوفاة). تم توقيع النموذج 4 بالوكالة نيابة عنها.
Deborah H. Telman，Gilead Sciences (GILD) 的执行副总裁、企业事务与总律师在 2025/09/10 报告了两笔交易。她获授了 1,315 份受限股票单位（RSU），每份可转化为一股股票，4 年内分阶段归属（第一年 25%，随后每季度 6.25%）。RSU 授予使 contingent ownership 增加 1,315 股。同日她还以每股 $115.25 的价格出售了 634 股。完成交易后，她的实际持股为 43,402 股（含未归属的 RSU 为 44,036 股）。Form 4 由其代理签署。
- Time‑based RSU grant aligns executive compensation with long‑term shareholder interests via multi‑year vesting
- Vesting schedule disclosed (25% at one year, then 6.25% quarterly) provides clarity on when shares may convert
- Insider sale of 634 shares at $115.25 reduces immediate insider shareholding and provides liquidity
- Unvested RSUs represent potential future dilution when they convert to common stock upon vesting
Insights
TL;DR: Standard executive compensation and a routine stock sale; aligns long-term incentives while realizing partial liquidity.
The filing shows a customary time‑based RSU award with a four‑year vesting schedule, which is typical for senior executives and supports alignment with shareholder interests over time. The concurrent sale of 634 shares at $115.25 appears to be a limited liquidity event and does not materially change post-transaction ownership levels. No unusual acceleration, insider trading plan disclosure, or derivative exercises are reported.
TL;DR: Net position essentially unchanged; grant increases potential future dilution modestly while sale provides cash at reported market price.
Post-transaction beneficial ownership remains sizeable at 43,402 shares with 1,315 RSUs outstanding. The RSU grant creates potential future issuance upon vesting but is a normal compensation tool. The sale at $115.25 provides realized proceeds but, given the scale relative to total holdings, is not a material shift in insider alignment from an investor perspective.
Deborah H. Telman, Vicepresidente Esecutivo per gli Affari Aziendali Corporate e Consigliere Generale di Gilead Sciences (GILD), ha riportato due transazioni il 09/10/2025. Le sono state attribuite 1.315 unità di azioni restritte (RSU), ciascuna delle quali si convertì in una azione, che maturano in quattro anni (il 25% al primo anno, poi il 6,25% trimestralmente). Il grant RSU ha aumentato la proprietà contingente di 1.315 azioni. Nella stessa data ha ceduto 634 azioni in una vendita al prezzo di $115,25 per azione. Dopo queste transazioni deteneva beneficialmente 43.402 azioni (44.036 inclusi gli RSU non maturi). Il Form 4 è stato firmato per procura per suo conto.
Deborah H. Telman, Vicepresidenta Ejecutiva de Asuntos Corporativos y Consejera General de Gilead Sciences (GILD), informó de dos transacciones el 09/10/2025. Se le otorgaron 1.315 unidades de acciones restringidas (RSU), cada una de las cuales se convierte en una acción, que vence en cuatro años (75% al año uno, luego 6.25% trimestralmente). La concesión de RSU aumentó la propiedad contingente en 1.315 acciones. En la misma fecha dispuso de 634 acciones en una venta a $115.25 por acción. Después de estas operaciones poseía de forma beneficiosa 43.402 acciones (44.036 incluyendo las RSU no vestidas). El Formulario 4 fue firmado por poder de representación en su nombre.
Deborah H. Telman, Gilead Sciences(GILD) 의 부사장 겸 기업 커뮤니케이션(또는 기업 관계) 및 일반 counsel,는 2025년 9월 10일에 두 건의 거래를 보고했다. 그녀는 1,315개의 제한 주식 단위(RSU)를 부여받았으며, 각 단위는 한 주식으로 전환되며 4년 동안 vesting된다(1년 차에 25%, 그 다음 매 분기 6.25%). RSU 부여는 거주 지분을 1,315주 증가시켰다. 같은 날 그녀는 634주를 처분했고 주당 가격은 $115.25였다. 이 거래 후 그녀의 실제 보유 주식은 43,402주였으며, 미 vest RSU를 포함하면 44,036주이다. Form 4는 그녀를 대신해 위임장으로 서명되었다.
Deborah H. Telman, Vice‑Présidente Exécutive des Affaires Corporatives et Conseillère Juridique Générale de Gilead Sciences (GILD), a déclaré deux transactions le 09/10/2025. Elle a reçu 1 315 unités d’actions restreintes (RSU), chacune se convertissant en une action, qui vestent sur quatre ans (25 % la première année, puis 6,25 % trimestriellement). L’octroi de RSU a augmenté la propriété éventuelle de 1 315 actions. À la même date, elle a cédé 634 actions lors d’une vente à $115,25 par action. Après ces transactions, elle détenait de manière bénéficiaire 43 402 actions (44 036 actions en incluant les RSU non vestées). Le Form 4 a été signé par procuration en son nom.
Deborah H. Telman, Executive Vice President, Corporate Affairs & General Counsel von Gilead Sciences (GILD), meldete zwei Transaktionen am 09/10/2025. Ihr wurden 1.315 Restricted Stock Units (RSUs) gewährt, von denen jede in eine Aktie umgewandelt wird und über vier Jahre vestet (25 % im ersten Jahr, dann vierteljährlich 6,25 %). Die RSU-Zuteilung erhöhte das contingent ownership um 1.315 Aktien. Am gleichen Datum veräußerte sie 634 Aktien zu einem Preis von $115,25 je Aktie. Nach diesen Transaktionen hielt sie vorteilhafterweise 43.402 Aktien (44.036 einschließlich der noch nicht vesteten RSUs). Das Form 4 wurde in Vollmacht zu ihren Gunsten unterzeichnet.
FAQ
What transactions did Deborah H. Telman report on Form 4 for GILD?
How many Gilead (GILD) shares does Telman beneficially own after the transactions?
What is the vesting schedule for the RSUs granted to Telman?
At what price were the shares sold by Telman?
Does the Form 4 indicate the sale was part of a trading plan (10b5-1)?
